德国痴呆症预防知识的社会人口统计差异:对有针对性的健康传播的影响
Pauline Albus1, Ann-Kristin Folkerts1, Josef Kessler1
1Medical Psychology | Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
The journal of prevention of Alzheimer's disease
|February 28, 2026
概括
公众对痴呆风险因素的认识正在提高,但知识缺口仍然存在,特别是关于医疗因素的知识缺口. 需要量身定制的教育策略,以解决因年龄,性别和教育水平而存在的意识差异,以有效预防痴呆症.
科学领域:
- 公共卫生 公共卫生
- 神经学 神经学
- 老年学是一门学科.
背景情况:
- 痴呆症是一个重大的全球健康挑战,但公众对其可预防性和可修改的风险因素的理解不足.
- 有限的知识阻碍了在德国实施有效的公共卫生策略来预防痴呆症.
- 影响痴呆症预防意识的社会人口学因素需要进一步调查.
研究的目的:
- 评估德国公众对痴呆症可预防性的认识.
- 评估不同人口群体对痴呆风险和保护因素的知识.
- 确定年龄,性别和教育对痴呆症预防知识的影响.
主要方法:
- 在德国,在2515名成年人中进行了一项在线的横截面调查.
- 用验证的调查项目评估了参与者对痴呆症,风险因素和可预防性的认识.
- 用回归模型分析了与年龄,性别和教育相关的知识分数.
主要成果:
- 虽然大多数德国人知道痴呆症是什么,但只有73%的人知道风险改变因素,38%的人怀疑其可预防性.
- 生活方式因素 (活动,饮食) 被广泛认可,但医疗风险 (心血管,脏疾病) 显著被忽视.
- 年龄较小,女性性别和高等教育与更大的知识相关,教育是最强的预测因素.
结论:
- 痴呆症预防意识比之前的德国研究更高,但具体的知识,特别是医疗因素,仍然有限.
- 根据年龄,性别和教育水平,意识和首选信息来源存在显著差异.
- 公共卫生倡议必须针对特定的人口群体量身定制,以提高痴呆症预防知识和参与度.
更多相关视频
相关概念视频
01:30Dementia
615
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
615
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
287
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
287
01:15Drug Dosing: Geriatric Patients
328
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
328
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
765
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
765
01:26Levels of Health Promotion and Illness Prevention
15.3K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
In primary prevention, actions taken before disease onset prevent the disease from...
15.3K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K